Clinical Trial Update: LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for LCAR-B38M cells in relapsed/refractory multiple myeloma (Phase 1/Phase 2) is provided, with unspecified status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LCAR-B38M (LCAR-B38M)

Snippet

Sponsor: Nanjing Legend Biotech Co. | Conditions: Refractory or Relapsed Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN